Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY 3,433.00
+22.00 (0.64%)
At close: Dec 26, 2025
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 19,765 employees as of March 31, 2025. The number of employees increased by 1,039 or 5.55% compared to the previous year.
Employees
19,765
Change (1Y)
1,039
Growth (1Y)
5.55%
Revenue / Employee
100.12M JPY
Profits / Employee
14.16M JPY
Market Cap
6.35T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 19,765 | 1,039 | 5.55% |
| Mar 31, 2024 | 18,726 | 1,291 | 7.40% |
| Mar 31, 2023 | 17,435 | 977 | 5.94% |
| Mar 31, 2022 | 16,458 | 425 | 2.65% |
| Mar 31, 2021 | 16,033 | 685 | 4.46% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| HOYA Corporation | 37,909 |
| Otsuka Holdings | 35,338 |
| Olympus | 29,297 |
| M3, Inc. | 15,360 |
| Astellas Pharma | 13,643 |
| Eisai | 10,917 |
| Kyowa Kirin | 5,669 |
Daiichi Sankyo Company News
- 6 days ago - AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA's Breakthrough Therapy Designation In US - Nasdaq
- 6 days ago - ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer - Nasdaq
- 12 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript - Seeking Alpha
- 12 days ago - AstraZeneca : ENHERTU Combination Approved In US For 1st-Line HER2-Positive Metastatic Breast Cancer - Nasdaq
- 12 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day - Slideshow - Seeking Alpha
- 12 days ago - AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Combo Gains FDA Approval - GuruFocus
- 13 days ago - US FDA approves Daiichi Sankyo's therapy to treat breast cancer - Reuters
- 13 days ago - Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research - PRNewsWire